BioSpace News Archive

Drug Development

Ipsen Suspends Dosing in Phase III FOP Trial Following Futility Analysis

The company hopes to resume the trials following an assessment of data.

January 24, 2020
·
2 min read
·
Alex Keown
Policy

Insys Founder Sentenced to 66 Months for Scheme to Boost Opioid Sales

Kapoor was found guilty in May 2019 of orchestrating kickback schemes to encourage doctors to boost prescriptions of Subsys, a powerful pain killer.

January 24, 2020
·
3 min read
·
Alex Keown
Drug Development

Genentech’s Tecentriq Misses Mark in Urothelial Cancer Trial

“Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival,” said Levi Garraway, Genentech’s chief medical officer and head of Global Product Development.

January 24, 2020
·
2 min read
·
Mark Terry
Business

Citing Decreased Sales, 23andMe Lays Off 14% of Workforce

The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.

January 24, 2020
·
3 min read
·
Mark Terry
Lone Star Bio

Researchers ID Promising 2-Drug Combo for Resistant Breast Cancer

Researchers are constantly finding drug combinations that help fight drug-resistant cancers. Researchers at the UT Southwestern Medical Center appeared to have found a new one using already approved drugs.

January 24, 2020
·
3 min read
·
Mark Terry
BioCapital

Clinical Catch-Up: Jan 20-24

The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.

January 24, 2020
·
6 min read
·
Mark Terry
FDA

Epizyme Wins FDA Approval for Epithelioid Sarcoma Drug

Robert Bazemore, president and chief executive officer of Epizyme, called the accelerated approval of Tezverik “a landmark event” for people with epithelioid sarcoma, a soft-tissue cancer.

January 24, 2020
·
2 min read
·
Alex Keown
Drug Development

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer’s regorafenib

CStone Pharmaceuticals recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with regorafenib, an oral multi-kinase inhibitor developed by Bayer Healthcare LLC.

January 24, 2020
·
6 min read
Deals

Anika Therapeutics Closes Acquisition of Parcus Medical

Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline

January 24, 2020
·
3 min read
Business

Horizon Therapeutics plc Announces Changes in Research and Development Organization

Horizon Therapeutics plc announced changes to its research and development organization structure.

January 24, 2020
·
8 min read